Cinnarizine EP Impurity A Reference Standard: Applications in Pharmaceutical Analysis
Pharmaceutical quality control depends on the reliable identification, monitoring, and quantification of impurities that may occur during drug substance manufacturing, formulation, storage, or degradation. For active pharmaceutical ingredients (APIs) such as cinnarizine, the availability of well-characterized impurity reference standards is essential for developing and validating analytical methods and demonstrating compliance with pharmacopoeial and regulatory requirements.
Cinnarizine EP Impurity A Reference Standard is an important analytical material for laboratories involved in the quality assessment of cinnarizine drug substances and products. Chemicea Pharmaceuticals supplies Cinnarizine EP Impurity A as part of its pharmaceutical impurity reference standard portfolio, supporting applications such as method validation, impurity profiling, forced degradation studies, stability testing, and pharmaceutical research.
According to Chemicea's product information, Cinnarizine EP Impurity A has CAS No. 841-77-0, CAT. No. CP-C76001, molecular formula C17H20N2, and molecular weight 252.36 g/mol. It is also identified by the chemical name 1-(Diphenylmethyl)piperazine and the synonym Norcyclizine.
Understanding Cinnarizine and Its Impurity Profile
Cinnarizine is a piperazine derivative used pharmaceutically for the management of conditions associated with vestibular disorders and motion sickness. Its chemical structure contains a diphenylmethylpiperazine moiety linked to a cinnamyl group. The structural complexity of the molecule means that impurities can arise from starting materials, intermediates, side reactions, stereochemical changes, or incomplete reactions during manufacturing.
The European Pharmacopoeia includes impurity controls as part of the quality assessment of cinnarizine. Analytical procedures can therefore require suitable reference materials to identify and quantify specified impurities. The European Pharmacopoeia monograph for cinnarizine specifically identifies impurity A within its impurity profile.
Cinnarizine EP Impurity A is chemically distinct from the parent API. Chemicea identifies the compound as 1-(Diphenylmethyl)piperazine, providing an appropriate analytical reference material for laboratories investigating this component in cinnarizine-related samples.
Product Profile of Cinnarizine EP Impurity A
Parameter | Information |
Product | Cinnarizine EP Impurity A |
CAT. No. | CP-C76001 |
CAS No. | 841-77-0 |
Chemical Name | 1-(Diphenylmethyl)piperazine |
Synonym | Norcyclizine |
Molecular Formula | C17H20N2 |
Molecular Weight | 252.36 g/mol |
Category | Impurity Standards |
The availability of these identifiers is important for analytical laboratories because reference standards are frequently selected based on chemical identity, CAS number, pharmacopoeial designation, catalog number, and intended analytical application. Chemicea provides product documentation such as COA and MSDS through its product platform.
What Is a Pharmaceutical Impurity Reference Standard?
An impurity reference standard is a characterized material used as an analytical benchmark. Unlike the API itself, an impurity standard represents a specific compound that may be present as a process-related impurity, degradation product, intermediate, or other related substance.
During chromatographic analysis, the reference standard helps analysts establish the identity and response characteristics of an impurity. A laboratory can compare the retention time and analytical response of the impurity in a test sample against the corresponding reference material.
Reference standards therefore play an important role in:
Impurity identification
Quantitative impurity analysis
Analytical method development
Method validation
Stability-indicating method development
Forced degradation studies
Batch release testing
Process development
Regulatory documentation
Investigations of unknown chromatographic peaks
Official pharmacopoeial reference substances are specifically established for prescribed compendial applications, while suitable secondary or working standards may be used for routine analytical purposes when appropriately qualified. The Indian Pharmacopoeia Commission notes that working standards can be standardized against official reference substances for routine analysis.
Applications of Cinnarizine EP Impurity A Reference Standard
1. HPLC Method Development
High-performance liquid chromatography (HPLC) is widely used for pharmaceutical impurity analysis. During development of a chromatographic method for cinnarizine, the presence of a Cinnarizine EP Impurity A reference standard allows analysts to determine whether a chromatographic peak corresponds to the specified impurity.
The standard can be used to evaluate retention time, chromatographic separation, peak response, and selectivity. This is particularly important when multiple structurally related substances may occur within the same sample.
A properly characterized impurity standard can therefore assist scientists in establishing an impurity profile that distinguishes the parent API from its related substances.
2. Analytical Method Validation
Analytical methods used for pharmaceutical quality control must demonstrate characteristics such as specificity, precision, accuracy, linearity, range, and robustness, depending on the intended application.
Cinnarizine EP Impurity A can serve as a critical test material during impurity-method validation. Analysts may prepare solutions containing known concentrations of the impurity and evaluate the ability of the analytical method to detect and quantify it.
For example, a validation study can examine whether the method can adequately distinguish Cinnarizine EP Impurity A from cinnarizine and other related compounds.
3. Stability Studies
Pharmaceutical products are subjected to stability studies to understand how their quality changes over time under specified storage conditions.
During stability testing, chromatographic analysis may reveal new or increasing peaks associated with degradation. Reference standards can help laboratories identify known impurities and distinguish them from unidentified degradation products.
For cinnarizine formulations, Cinnarizine EP Impurity A can therefore support impurity monitoring when the analytical procedure includes this specified impurity.
4. Forced Degradation Studies
Forced degradation involves deliberately exposing an API or pharmaceutical product to stress conditions such as heat, humidity, oxidation, hydrolysis, or light.
The objective is to understand degradation pathways and demonstrate that an analytical procedure is capable of detecting changes in the drug substance or product.
Cinnarizine EP Impurity A can be used as a comparison material when assessing stressed samples. Its inclusion in analytical investigations can help researchers establish the identity and behavior of the corresponding impurity peak.
Chemicea specifically lists Cinnarizine EP Impurity A for applications including method validation, ANDA filing, forced degradation studies, identification standards, and DMF filing.
5. Identification of Unknown or Specified Peaks
One of the fundamental challenges in pharmaceutical chromatography is determining the identity of peaks other than the principal API peak.
A reference standard provides a direct analytical comparison. If the retention time and other analytical characteristics correspond between the sample and reference material, scientists can obtain stronger evidence for peak assignment.
Where required, additional analytical techniques such as LC-MS, NMR, IR, or other spectroscopic techniques can be used to support structural characterization.
6. Quality Control of Cinnarizine API
API manufacturers and pharmaceutical companies routinely monitor related substances to ensure consistency between production batches.
Cinnarizine EP Impurity A can be incorporated into quality-control workflows where the specified impurity needs to be identified or quantified. This enables laboratories to compare analytical results against established specifications and investigate unexpected variations.
Reliable impurity standards are particularly important when analytical laboratories are transferring methods between facilities or instruments because consistent reference materials help support reproducibility.
Role in Regulatory and Pharmaceutical Documentation
Impurity characterization is an important part of pharmaceutical development and regulatory submissions. Data generated during impurity profiling, analytical method validation, stability studies, and process development may contribute to regulatory documentation.
For companies preparing DMF, ANDA, or other regulatory submissions, having appropriate impurity reference materials can help establish the identity and analytical control strategy for specified related substances.
The value of an impurity standard extends beyond simply having a vial of a chemical compound. Laboratories need confidence in its identity, characterization, documentation, and suitability for its intended analytical purpose.
Chemicea's Cinnarizine-related portfolio also includes additional materials such as Cinnarizine EP Impurities B, C, D, and E, along with N-nitroso Cinnarizine EP Impurity A and other related compounds. This broader portfolio can support laboratories performing comprehensive impurity profiling rather than evaluating a single impurity in isolation.
Why Characterization Matters
The analytical value of an impurity reference standard depends strongly on its characterization and documentation.
For pharmaceutical laboratories, important considerations include:
Confirmed chemical identity
Appropriate purity assessment
CAS number and molecular information
Analytical characterization
Certificate of Analysis (COA)
Safety documentation
Suitable storage and handling information
Traceability where applicable
Consistent batch quality
Reference-standard suppliers therefore play an important role in the pharmaceutical analytical ecosystem. A dependable supplier can help laboratories obtain materials required for method development, validation, QC testing, and regulatory projects without compromising analytical consistency.
Chemicea Pharmaceuticals: Supporting Pharmaceutical Analytical Research
Chemicea Pharmaceuticals specializes in pharmaceutical reference standards and related analytical materials, with a portfolio covering pharmaceutical impurities, process impurities, degradation products, nitrosamines, metabolites, glucuronides, and stable-isotope-labeled compounds.
For Cinnarizine-related analytical requirements, Chemicea provides a dedicated range of reference materials. Cinnarizine EP Impurity A is available under CAT. No. CP-C76001, while additional cinnarizine-related products can be supplied through the company's portfolio and custom-synthesis capabilities.
This combination of reference-standard supply and chemistry expertise is particularly useful for pharmaceutical companies and analytical laboratories that require materials for specialized projects.
Where a required impurity or related substance is not available as a standard catalog item, custom synthesis capabilities can provide an additional route for obtaining specialized analytical compounds. Chemicea's current Cinnarizine-related listing demonstrates this model, with several related compounds identified as available through custom synthesis.
Importance of Reliable Impurity Standards in Modern Pharmaceutical QC
Modern pharmaceutical quality control increasingly depends on sensitive analytical techniques capable of detecting impurities at low concentrations. As analytical instrumentation becomes more sensitive, laboratories may identify trace-level compounds that were previously difficult to observe.
This creates a corresponding need for reliable reference materials.
An impurity reference standard provides a known point of comparison and supports the transition from simply observing a chromatographic peak to scientifically establishing its identity and concentration.
For cinnarizine manufacturers, formulation developers, contract research organizations, and QC laboratories, Cinnarizine EP Impurity A can therefore be an important component of a comprehensive analytical reference-standard collection.
Conclusion
Cinnarizine EP Impurity A Reference Standard is an important analytical material for laboratories involved in the quality control and development of cinnarizine pharmaceutical products. With CAS No. 841-77-0, CAT. No. CP-C76001, molecular formula C17H20N2, and the chemical identity 1-(Diphenylmethyl)piperazine, it provides a defined reference point for impurity-related analytical investigations.
Its applications extend across HPLC method development, analytical method validation, impurity identification, stability testing, forced degradation studies, QC testing, and regulatory documentation. The European Pharmacopoeia's cinnarizine monograph also incorporates impurity controls, highlighting the importance of suitable analytical reference materials in compendial testing.
For pharmaceutical companies seeking dependable impurity standards, Chemicea Pharmaceuticals offers Cinnarizine EP Impurity A together with a broader range of cinnarizine-related impurities and specialized compounds. Through its reference-standard portfolio and custom-synthesis capabilities, Chemicea supports pharmaceutical analytical research, quality control, method development, and regulatory requirements.
Chemicea Pharmaceuticals can be a valuable analytical-material partner for organizations requiring high-quality pharmaceutical impurity reference standards for research, development, quality control, and regulatory applications.
Comments